Akero Therapeutics

Akero Therapeutics is a biopharmaceutical company focused on developing innovative treatments for non-alcoholic steatohepatitis (NASH), a severe liver disease affecting millions globally. The company's lead product, AKR-001, is designed to address NASH holistically by reducing liver fat, inflammation, and fibrosis, while also improving lipoprotein profiles to lower cardiovascular risks. Akero operates in the healthcare and pharmaceutical market, targeting patients with NASH and related metabolic disorders. The business model revolves around research and development of therapeutic candidates, progressing through clinical trials, and eventually seeking regulatory approval for commercialization. Revenue is generated through partnerships, licensing agreements, and future product sales. Keywords: biopharmaceutical, NASH, liver disease, AKR-001, metabolic balance, fibrosis, inflammation, lipoprotein, cardiovascular, clinical trials.